A Phase 2 interventional study of ENERGI-F703EB Cream and Matched vehicle cream in Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa and Epidermolysis Bullosa Simplex, sponsored by Energenesis Biomedical Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 for screening, an 8-week period from Visit 2 to Visit 7 for treatment, and a 4-week period from Visit 7 to Visit 9 for safety follow-up.
86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.
This study's planned enrollment of 24 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.
Browse Epidermolysis Bullosa studies →Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject is eligible for the study if all of the following apply:
Subject has clinical diagnosis and laboratory evidence of EB simplex, junctional EB, or dystrophic EB.
Note: Subjects may be included if diagnostic testing confirms subtype. Acceptable diagnostic testing methods include transmission electron microscopy and immunofluorescence studies.
Subject's target EB lesions in the matched target lesion pair fulfill all of the following criteria at the Baseline Visit (Visit 2):
Female subjects are eligible only if all of the following apply:
Exclusion Criteria:
A subject meeting any of the exclusion criteria will be excluded from study participation:
Subject's target EB lesions in the matched target lesion pair fulfill any of the following criteria:
With any of the following impaired hepatic or renal functions at the Screening Visit:
Note: For eGFR, the CKD-EPI creatinine equation (2021) will be used: eGFR (mL/min/1.73 m2) = 142 × min (SCr/K, 1)α × max (SCr/K, 1)-1.200 × 0.9938age × (1.012 if female); where:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ENERGI-F703EB Cream
Drug: Matched vehicle cream
Standard of care and ENERGI-F703EB Cream is applied for the treatment of Epidermolysis Bullosa
Standard of care and matched vehicle cream is applied for the treatment of Epidermolysis Bullosa
Incidence of Local Target Lesion Adverse Events
Number of local target lesion adverse events with onset during the specified assessment period.
Time frame: Day 1 through Day 85
Incidence of Adverse Events Excluding Local Target Lesion Adverse Events
Number of adverse events, excluding local target lesion adverse events, with onset during the specified assessment period.
Time frame: Day 1 through Day 85
Number of participants with abnormalities in vital signs
Vital signs measurement consist of systolic and diastolic blood pressure, respiratory rate, pulse rate, and body temperature.
Time frame: Baseline to Days 15, 29, 43, 57, 71, and 85
Number of participants with abnormalities in laboratory examination results
Laboratory tests to be measured in this study will consist of the following: * Hematology: white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, platelets, red blood cells (RBC). * Biochemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, glucose, HbA1c, serum creatinine, blood urea nitrogen (BUN), albumin, prealbumin, and estimated glomerular filtration rate (eGFR). * Urinalysis: chemical strip (specific gravity, pH, occult blood, leukocytes, glucose, protein, ketones, bilirubin.
Time frame: Baseline to Days 57 and 85
Number of Subjects With Abnormal Physical Examination Findings
Number of subjects with abnormal physical examination findings at Day 57 and Day 85.
Time frame: Day 57 and Day 85
Proportion of Target Lesions With Complete Lesion Closure
Proportion of target lesions with complete lesion closure as assessed by the investigator at each specified visit.
Time frame: Days 15, 29, 43, and 57
Intra-Subject Comparison of Target Lesion Re-epithelialization
Intra-subject comparison of target lesions with respect to re-epithelialization as assessed by the investigator at each specified visit.
Time frame: Days 15, 29, 43, and 57
Net Change From Baseline in Target Lesion Size
Net change in target lesion size from baseline at each specified visit.
Time frame: Baseline to Days 15, 29, 43, and 57
Percent Change From Baseline in Target Lesion Size
Percent change in target lesion size from baseline at each specified visit.
Time frame: Baseline to Days 15, 29, 43, and 57
Time to First Target Lesion Closure
Time from baseline to the first occurrence of target lesion closure.
Time frame: Baseline through Day 57
Proportion of Target Lesions With at Least 50% Lesion Closure
Proportion of target lesions achieving at least 50% lesion closure at each specified visit.
Time frame: Days 15, 29, 43, and 57
Proportion of Target Lesions With at Least 75% Lesion Closure
Proportion of target lesions achieving at least 75% lesion closure at each specified visit.
Time frame: Days 15, 29, 43, and 57
Proportion of Target Lesions With at Least One Complete Lesion Closure
Proportion of target lesions that achieved complete lesion closure at least once, as assessed by the investigator, at any assessment up to Visit 7, regardless of subsequent reopening.
Time frame: Baseline through Day 57
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Energenesis Biomedical Co., Ltd. →